Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the hot stocks to buy with huge upside potential. On October 10, B. Riley raised the firm’s price target on Ovid Therapeutics to $5 from$3 and kept a Buy rating on the shares. This price target lift came as a result of strong Phase 1 biomarker results for OV329, as the analyst reported. The results showed superior efficacy compared to vigabatrin, notably without the associated ocular toxicity. B. Riley Lifts Ovid Therapeutics (OVID) PT to $5 on Strong OV329 ...